von Moos, R., Hawle, H., Hayoz, S., Cathomas, R., Müller, A., Schmid, S., Pagani, O., Wehrhahn, T., Rauch, D., Anchisi, S., Hermanns, T., Fehr, M., Stoll, S., Bützberger, P., Zweifel, M., Huber, U., Fuhrer, A. C., Schär, C., Gillessen, S., & Templeton, A. J. (n.d.). 1703PIncidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE). Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095492991.0x00002d